ANDAORALPOWDER
Approved
Aug 1996
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LOCHOLEST LIGHT (cholestyramine for oral suspension) by Molecular Devices is bile-acid binding activity [moa]. First approved in 1996.
Drug data last refreshed 19h ago
Mechanism of Action
Bile-acid Binding Activity
Pharmacologic Class:
Bile Acid Sequestrant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LOCHOLEST LIGHT at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.